6月19日，由《中国证券报》评选的第三届基金投顾金牛奖榜单揭晓，建信基金荣获"基金投顾新锐金牛 奖"，是唯一一家获得该奖项的银行系基金公司。建信基金于2021年获得公募基金投顾业务试点展业资 格，在组合投资管理上积累了较为丰富的实战经验。此外，鉴于在投资者教育方面的创新和长期实践， 建信基金此次还荣获"大学生投教创新金牛奖"。 作为资本市场和资管行业颇具分量的奖项，中国证券报主办的"金牛奖"凭借着对公正、公平、公开、有 公信力原则的严格执行，受到监管层和行业的广泛认可，已成为中国资本市场最具公信力和影响力的权 威奖项之一。第三届基金投顾金牛奖评选在充分调研、核实信息数据的基础上，结合定量和定性两部 分，从顾问服务、投资者获得感、智能科技、业务创新等方面对基金投顾机构进行综合评价。 投前，提供个性化的"产品配置建议"。根据试点期间的展业经验和客户反馈，建信基金开发了"以终为 始"的养老财富管理模型，针对中低风险偏好的客户，从退休年限倒推出最大的含权产品配置比例，通 过对含权资产的配置，实现养老财富增值的目标。投中，通过专业模型引导客户掌握科学的投资节奏。 养老账户的资金流稳定且持续，大部分客户仍然习惯于每年入金 ...

答：公司共承建了三个海绵城市项目，分别为河北迁安项目、 云南玉溪项目、四川遂宁项目，项目涵盖海绵城市全流程规划、 设计、施工及运营。 四、公司海绵城市项目的业务模式及近况？ 1 三、公司与同方投资仲裁案的由来及最新的进展情况。 答：公司与同方投资仲裁案的相关内容均已按照监管规定详 细披露。目前，同方投资仍然不服判决，已向最高人民法院提起 再审申请，现处于再审立案审查阶段，是否符合再审立案条件尚 需最高人民法院审查后裁定。公司已聘请专业的法律团队积极应 对，确保应诉工作有序推进，最大限度降低再审案件对公司的影 响。 证券代码：000068 证券简称：华控赛格 深圳华控赛格股份有限公司 投资者关系活动记录表 编号：2025-01 | 投资者关系活动 | 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | --- | --- | | 类别 | □新闻发布会 □路演活动 现场参观 □其他 远东宏信有限公司 翁烨丹 | | | 凯石基金管理有限公司 陈林 | | 参与单位名称及 | 深圳良品私域科技服务有限公司 熊辉 | | 人员姓名 | 深圳源通千相投资有限公司 刘美诺 | | | 深圳创华启盛顾问咨询 ...

Company Overview - Ivanhoe Electric's shares increased by 8.7% to $9.17 in the last trading session, with a notable trading volume, contributing to a 14.7% gain over the past four weeks [1][2] Project Development - The rise in share price follows the completion of the Preliminary Feasibility Study for the Santa Cruz Copper Project in Arizona, marking a significant milestone for securing long-term project financing [2] - The Study emphasizes advanced engineering design from extraction to processing, ensuring the project's bankability and readiness for financing [3] - Construction for the Santa Cruz project is planned to commence in the first half of 2026, aiming for first copper cathode production by 2028 [3] Financial Performance - Ivanhoe Electric is projected to report a quarterly loss of $0.13 per share, reflecting a year-over-year increase of 66.7%, with expected revenues of $0.74 million, up 37% from the previous year [4] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [5] Industry Context - Ivanhoe Electric holds a Zacks Rank of 3 (Hold) within the Zacks Mining - Miscellaneous industry, contrasting with Alpha Metallurgical, which has a Zacks Rank of 5 (Strong Sell) and has seen a 13.3% decline over the past month [6]

Core Viewpoint - Coinbase has been recognized as a leading player in the cryptocurrency sector, with analysts upgrading its price target significantly, reflecting strong growth potential and market position [2][3]. Group 1: Analyst Insights - Bernstein analysts upgraded Coinbase's price target to $510 from $310, maintaining an "Outperform" rating, and described it as the "most misunderstood company" in the crypto space [2]. - Analysts highlighted Coinbase's unique position as the only cryptocurrency company in the S&P 500, its dominance in U.S. crypto trading, and its leadership in the stablecoin exchange market [3]. - Coinbase has diversified its offerings beyond trading, including institutional custody, Base blockchain infrastructure, and a Prime lending desk [3]. Group 2: Price Targets and Broker Ratings - The average price target for Coinbase, based on 26 analysts, is $275.40, indicating a potential decline of 20.13% from its closing price of $344.82 on June 24 [4]. - Coinbase has an average brokerage recommendation (ABR) of 2.14, indicating a shift from an ABR of 2.27 a month ago, with 13 Strong Buy and one Buy recommendations [5][6]. Group 3: Earnings Estimates - The Zacks Consensus earnings estimate for Coinbase's current quarter is $0.91, up from $0.83 a month ago, with the full-year estimate now at $2.96 per share, an increase from $2.41 [7]. Group 4: Market Trends - Coinbase's stock has surged approximately 40% this year, partly due to the Senate's passage of the GENIUS Act, which aims to create a federal framework for stablecoins [8]. - The positive market sentiment is also reflected in the strong gains of other crypto-related companies, indicating increasing institutional adoption of bitcoin and optimism around stablecoin regulation [8]. Group 5: Valuation Concerns - Despite the positive outlook, Coinbase shares are considered to lack value, with a trailing 12-month price-to-earnings (PE) ratio of 49.12X compared to 15.16X for the Financial - Miscellaneous Services industry [9]. Group 6: Investment Options - Investors looking to mitigate risks while capitalizing on Coinbase's momentum may consider COIN-heavy ETFs, which include several funds with at least 10% exposure to Coinbase [10][11].

Core Insights - PayPal has entered into a partnership with the Big Ten and Big 12 conferences to facilitate compensation for student-athletes through its platform [1][3] - This agreement follows a significant court settlement in the House v. NCAA case, which allows schools to compensate student-athletes for the first time, enabling up to $20.5 million in payments to current athletes and $2.8 billion to former players [2] Group 1: Partnership Details - The new agreement allows Big Ten and Big 12 athletic departments to use PayPal exclusively for distributing payments to student-athletes [3] - The initial rollout of this payment system is expected to begin in the summer, coinciding with the effective date of the House settlement on July 1 [3] Group 2: Payment Features - The partnership will enable students at Big Ten and Big 12 universities to receive their compensation quickly and securely, with the option to pay college tuition via PayPal [4] - PayPal aims to become a preferred payment partner at select schools, enhancing the financial experience for student-athletes [4] Group 3: Venmo's Role - PayPal's mobile payment service Venmo is expanding its involvement in college sports, becoming the presenting partner for the first-ever Big Ten Rivalry Series and the official partner of the Big 12 Conference [5][6] - Venmo will also facilitate transactions at college bookstores and for campus athletics, covering items such as tickets, concessions, and merchandise [6] Group 4: Conference Expansion - The Big Ten Conference has expanded to 18 schools, including notable institutions like the University of Maryland and Ohio State University [7] - The Big 12 Conference comprises 16 schools, including Arizona State University and the University of Central Florida [7]

Core Insights - ZyVersa Therapeutics, Inc. has initiated patient recruitment for its VAR 200 Phase 2a clinical study targeting diabetic kidney disease (DKD) [1][2] - VAR 200 is designed to address renal lipotoxicity by removing excess lipids from the kidneys, which is a significant factor in the progression of kidney diseases [3][7] - The study aims to evaluate the efficacy and safety of VAR 200 in patients with type 2 diabetes and DKD, with preliminary data expected in the second half of 2025 [7] Company Overview - ZyVersa is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for renal and inflammatory diseases with significant unmet medical needs [8] - The company is advancing a therapeutic pipeline that includes VAR 200 and another program targeting inflammation [8] Clinical Study Details - The VAR 200 Phase 2a trial will be an open-label study conducted at one to two US sites, enrolling an adequate number of subjects to complete eight [2][7] - The primary efficacy endpoint is the percent change from baseline to week 12 in urinary albumin to creatinine ratio, with treatment lasting 12 weeks followed by a four-week follow-up [2][7] Drug Mechanism and Indications - VAR 200, a Cholesterol Efflux Mediator™, is an injectable drug that aims to reduce renal lipid accumulation, which damages the kidney's filtration system [3][5] - Preclinical studies have shown that VAR 200 can reduce cholesterol and lipid levels, protect against renal injury and fibrosis, and improve proteinuria in various kidney disease models [4][7] Future Prospects - The lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS), with plans to expand indications based on the results of the ongoing trials [5][7] - The initiation of patient recruitment is considered a key milestone in the development of VAR 200, with the potential to be a first-in-class treatment for kidney disease [7]

新股上市数量、首发募资金额，同比均有所回升，2025年上半年临近结束，A股IPO出现回暖迹象。 A股上半年新股数量及募资金额实现同比增长， Wind数据显示，截至6月26日，A股年内共有51只新股上市，首发募资总额373.55亿元，同比分别增长 约16%、15%。首发市盈率平均值也较去年同期有所下降，新股上市首日平均涨幅则高于去年同期水 平，且上半年新股零破发。 港股则掀起上市热潮 ，"A+H"热度持续攀升。市场预计，港股上半年新股上市数量将达到43只，募资 总额预计达到1067亿港元，募资总额增长超过675%，其中A股上市公司赴港上市的募资总额占比超过 七成。 上半年A股IPO同比小幅回暖 Wind数据显示，截至6月26日，A股已有51只新股上市，相较去年同期的44只，同比增长约16%。 从上市板块分布来看，创业板新股数量居前。51只新股中的20只来自创业板，18只来自沪深主板，7只 来自科创板，6只来自北交所。 相较去年同期，整体募资规模实现小幅增长。上半年已上市的新股，募资总额合计373.55亿元，同比增 长约15%。其中，9只新股募资金额超过10亿元，中策橡胶（603049.SH）首发募资金额最高，达 ...

此时，市场关注的焦点是：创新药行情走到哪里了？究竟是"绝对底部"还是"炒作尾声"？ 据21世纪经济报道记者了解，目前不少基金经理持乐观态度，认为创新药行情还没有走完，但认为当前 创新药存在分化现象，一部分好公司仍在地板价，增长潜力巨大；但一部分垃圾股则存在巨大泡沫，炒 作已至尾声，应谨防踩坑。 创新药基金领涨 今年上半年，重仓创新药的基金表现优异。 21世纪经济报道特约记者 庞华玮 广州报道 近期，创新药板块震荡调整。 截至6月25日，今年以来，港股创新药指数上涨65.50%，万得创新药指数上涨24.83%。 值得一提的是，近两周创新药板块震荡调整期，有资金开始持续买入港股创新药ETF，该基金份额由 91.48亿份增至114.82亿份，增幅高达26%。 此外，从近期一些基金涨跌走势与创新药行情同步来推测，部分主动权益基金可能在二季度创新药上涨 后追高买入创新药，尤其是一批医药基金。 31只重仓创新药的头部基金中，包括19只主动权益基金，6只被动基金，6只QDII基金。 具体来看，今年重仓创新药基金净值涨幅TOP10为：汇添富香港优势精选A（88.98%）、长城医药产业 精选A（76.76%）、永赢医药创新智选 ...

6月26日-27日，第十一届广州国际投资年会在广州市白云国际会堂举行。1000名全球商业精英奔赴广 州，共绘投资发展图景，共逐产业创新浪潮。 本届年会由广州市人民政府主办，广州市投资发展委员会办公室承办。年会延续历届年会的"投资广州· 投资未来"的主题，同时以"建设具有经典魅力和时代活力的中心型世界城市"为年度主题，设置主题大 会、闭门会议、产业发展空间推介、广州之夜、产业考察等5大系列活动，并通过网络直播吸引超万名 观众在线观看。 一批企业家代表现场分享产业前沿趋势和在穗投资发展愿景；一批重大项目现场展示签约成果，德勤作 广州投资发展环境解读，胡润研究院发布《2025全球独角兽榜》，首批广州"城市合作人"集中授牌…… 本届大会期间，5个关键产业发展办公室集中亮相，系统推介广州"12218"现代化产业体系布局和机遇。 开放活力的广州面向全球，发出招商引资的最强音！ 一批重点项目落子 1600亿投资展示广州强磁场 畅谈投资广州新规划 全球投资者坚定看好广州 大会上，国内外知名企业的企业家进行发言分享。广州营商环境一流、创新氛围浓厚、产业配套完备， 经济发展活力十足、前景无限，期待在更广领域、更深层次加强与广州对 ...

IDG资本投资顾问（北京）有限公司董事长熊晓鸽表示，今年广州公布了"12218"现代化产业体系这张 新蓝图，这是广州制造业立市的新根基，也是产业升级的"新密码"，让投资机构感到格外兴奋。IDG 资 本从1997年起便非常重视布局广东省和广州市的优质企业，累计投资的广州企业已经有56家，投资金额 超80亿元，覆盖新能源、自动驾驶、先进制造、医疗健康等新经济领域，包括小鹏汽车、希音、文远知 行等独角兽。IDG资本未来将与广州国企协同，在并购和产业投资领域为广州市引入新能源、半导体、 先进制造、文化科技等重点发展领域的优质项目和大项目，支持广州建设"12218"现代化产业体系。 独角兽企业聚集的广州，正在迸发更大的创新潜力，赋能城市经济发展。 （文章来源：广州日报） 胡润百富董事长兼首席调研官胡润在年会上发布《2025全球独角兽榜》，"广州目前有24家独角兽企 业，数量虽与去年持平，但背后变化显著。今年，文远知行、小马智行因成功上市而不再列入榜单，其 中文远知行成为全球通用自动驾驶公司第一股，现价值160亿元；小马智行成为全球无人驾驶出租车第 一股，现价值340亿元。与此同时，广州迎来了两家新晋独角兽企业——车规级 ...